Pre-clinical modeling studying RET fusion driven cancer cell lines and patient-derived xenograft (PDX) models first confirmed the activity of MKIs through decreased RET autophosphorylation and inhibition of cell proliferation [35,106,107,108,109,110,111]. This evidence concerns the gene RET and cancer.